Peter Wildgoose

4.7k total citations · 1 hit paper
53 papers, 2.4k citations indexed

About

Peter Wildgoose is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Hematology. According to data from OpenAlex, Peter Wildgoose has authored 53 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Cardiology and Cardiovascular Medicine, 20 papers in Internal Medicine and 18 papers in Hematology. Recurrent topics in Peter Wildgoose's work include Atrial Fibrillation Management and Outcomes (28 papers), Venous Thromboembolism Diagnosis and Management (20 papers) and Blood Coagulation and Thrombosis Mechanisms (16 papers). Peter Wildgoose is often cited by papers focused on Atrial Fibrillation Management and Outcomes (28 papers), Venous Thromboembolism Diagnosis and Management (20 papers) and Blood Coagulation and Thrombosis Mechanisms (16 papers). Peter Wildgoose collaborates with scholars based in United States, Germany and United Kingdom. Peter Wildgoose's co-authors include Martin van Eickels, Roxana Mehran, Eric D. Peterson, Christoph Bode, Keith A.A. Fox, Gregory Y.H. Lip, Marc Cohen, Freek W.A. Verheugt, Steen Husted and Jonathan L. Halperin and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Peter Wildgoose

53 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

2016 942 citations C. Michael Gibson, Roxana Mehran et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Wildgoose United States	21	1.8k	780	455	319	157	53	2.4k
Michael Zuehlsdorf Germany	15	1.9k 1.1×	1.6k 2.0×	536 1.2×	256 0.8×	89 0.6×	25	2.3k
Isabell Bernlochner Germany	23	993 0.6×	376 0.5×	364 0.8×	505 1.6×	61 0.4×	62	1.4k
Anthony R. Porcari United States	12	820 0.5×	880 1.1×	189 0.4×	199 0.6×	30 0.2×	21	1.4k
Erika Gyzander Sweden	14	378 0.2×	288 0.4×	456 1.0×	224 0.7×	91 0.6×	20	1.2k
Martin Quinn Ireland	19	959 0.5×	248 0.3×	267 0.6×	643 2.0×	16 0.1×	45	1.6k
Beate Luxembourg Germany	17	231 0.1×	238 0.3×	293 0.6×	135 0.4×	54 0.3×	33	706
Gian Marco Podda Italy	18	224 0.1×	228 0.3×	469 1.0×	148 0.5×	148 0.9×	75	991
Joan Monteagudo Spain	16	128 0.1×	108 0.1×	288 0.6×	174 0.5×	59 0.4×	31	974
James Hanyok United States	10	594 0.3×	214 0.3×	62 0.1×	276 0.9×	29 0.2×	21	952
Osamu Okada Japan	17	319 0.2×	226 0.3×	41 0.1×	154 0.5×	102 0.6×	54	884

Countries citing papers authored by Peter Wildgoose

Since Specialization

Citations

This map shows the geographic impact of Peter Wildgoose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Wildgoose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Wildgoose more than expected).

Fields of papers citing papers by Peter Wildgoose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Wildgoose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Wildgoose. The network helps show where Peter Wildgoose may publish in the future.

Co-authorship network of co-authors of Peter Wildgoose

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Wildgoose. A scholar is included among the top collaborators of Peter Wildgoose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Wildgoose. Peter Wildgoose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mones, Jodi V., Michael B. Streiff, Alok A. Khorana, et al.. (2021). Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial. Research and Practice in Thrombosis and Haemostasis. 5(5). e12549–e12549. 9 indexed citations

Khorana, Alok A., John Barnard, Ted Wun, et al.. (2021). Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI. Blood Advances. 6(4). 1212–1221. 9 indexed citations

Weaver, James, Azza Shoaibi, Shujian Wu, et al.. (2021). Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA. Drug Safety. 44(4). 479–497. 9 indexed citations

Chi, Gerald, Megan K. Yee, Arzu Kalaycı, et al.. (2018). Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis. 46(3). 346–350. 8 indexed citations

Peacock, W. Frank, Christopher Kabrhel, C. A. Keay, et al.. (2017). 70 Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism from the Emergency Department. Annals of Emergency Medicine. 70(4). S29–S30. 2 indexed citations

Nguyen, Elaine, Craig I Coleman, W. Frank Peacock, et al.. (2017). Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis. BMC Pulmonary Medicine. 17(1). 37–37. 2 indexed citations

Gibson, C. Michael, Duane S. Pinto, Gerald Chi, et al.. (2016). Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation. 135(4). 323–333. 64 indexed citations

Coleman, C. Norman, et al.. (2016). Outcomes related to variation in hospital pulmonary embolus observation stay utilization. Value in Health. 19(3). A56–A56. 1 indexed citations

Weeda, Erin R., W. Frank Peacock, Gregory J. Fermann, et al.. (2016). Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism. Journal of Thrombosis and Thrombolysis. 42(4). 513–519. 5 indexed citations

10.

Nelson, Winnie W., et al.. (2015). International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation. American Journal of Cardiovascular Drugs. 15(3). 205–211. 32 indexed citations

11.

Ezekowitz, Michael D., Riccardo Cappato, Allan L. Klein, et al.. (2014). Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. American Heart Journal. 167(5). 646–652. 19 indexed citations

12.

Nelson, Winnie W., et al.. (2013). Impact of Co-morbidities and Patient Characteristics on International Normalized Ratio Control Over Time in Patients With Nonvalvular Atrial Fibrillation. The American Journal of Cardiology. 112(4). 509–512. 48 indexed citations

13.

Choi, Jiyoon, C.V. Damaraju, Roger M. Mills, et al.. (2012). IMPACT OF COMORBIDITIES ON TIME IN THERAPEUTIC RANGE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION. Journal of the American College of Cardiology. 59(13). E1855–E1855. 3 indexed citations

14.

Kwong, Louis M., Kristin D. Kistler, Roger M. Mills, Peter Wildgoose, & Winslow Klaskala. (2012). Thromboprophylaxis, bleeding and post-operative prosthetic joint infection in total hip and knee arthroplasty: a comprehensive literature review. Expert Opinion on Pharmacotherapy. 13(3). 333–344. 20 indexed citations

15.

Mills, Roger M., Richard Berkowitz, C.V. Damaraju, Lisa K. Jennings, & Peter Wildgoose. (2012). Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: The Safe, Simple Transitions (SST) study. Thrombosis Research. 130(5). 709–715. 8 indexed citations

16.

Hull, Russell D., Sebastian Schellong, Victor F. Tapson, et al.. (2006). Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study. Journal of Thrombosis and Thrombolysis. 22(1). 31–38. 63 indexed citations

17.

Matter, Hans, et al.. (2001). Solid-phase optimisation of achiral amidinobenzyl indoles as potent and selective factor Xa inhibitors. Bioorganic & Medicinal Chemistry Letters. 11(2). 227–230. 12 indexed citations

18.

Birktoft, Jens J., et al.. (1995). High Affinity Ca2+-binding Site in the Serine Protease Domain of Human Factor VIIa and Its Role in Tissue Factor Binding and Development of Catalytic Activity. Journal of Biological Chemistry. 270(26). 15523–15530. 51 indexed citations

19.

Thomsen, Mads Krogsgaard, Peter Wildgoose, Povl Nilsson, & Ulla Hedner. (1993). Accumulation of the Recombinant Factor VIIa in Rat Bone: Importance of the Gla‐Domain and Relevance to Factor IX, another Vitamin K‐Dependent Clotting Factor. Pharmacology & Toxicology. 73(3). 127–132. 11 indexed citations

20.

Nordfang, Ole, et al.. (1991). The C-terminus of tissue factor pathway inhibitor (TFPI) is essential to its anticoagulant activity. Biochemistry. 30(43). 10371–10376. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact